Benchmarking the Pharma Industry’s HEOR Functions
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Benchmarking the Pharma Industry’s HEOR Functions

on

  • 629 views

This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies. ...

This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies.
ISR details best practices, common approaches, as well as explains alternative styles so companies can use these assessments as a yard stick against which to measure, modify, and improve their own HEOR structures.

Statistics

Views

Total Views
629
Views on SlideShare
629
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Benchmarking the Pharma Industry’s HEOR Functions Document Transcript

  • 1. Benchmarking the Pharma Industry’s HEOR Functions Info@ISRreports.com ©2013 Industry Standard Research www.ISRreports.com PREVIEW
  • 2. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 2 act with confidence Report Overview This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies. ISR details best practices, common approaches, as well as explains alternative styles so companies can use these assessments as a yard stick against which to measure, modify, and improve their own HEOR structures. Major Sections: 1. Understanding the HEOR Function • HEOR Employees • HEOR Work 2. HEOR Department Benchmarking • Division of Work • Department Structure • Organizational Alignment • Outsourcing • Product Budgets Q4,2013Publication Date 55Pages Learn how you can use this report. Methodologies: ISR interviewed 17 senior employees with decision-making responsibilities in HEOR departments among the top 50 largest pharmaceutical companies. Pharma company rankings were determined by the “2013 Pharm Exec Top 50” pharmaceutical companies based on 2012 Rx Sales. • Global HEOR headquarters respondents: 13 • Regional headquarters or country affiliate respondents: 4 The titles below are held by our interviewees: • Vice President, Global HEOR • Director, Global HEOR (4) • Director, Global Health Outcomes • Director, Global Health Economics and Market Access • Director, HEOR (4) • Group Director, Global HEOR • Associate Director, HEOR (2) • Deputy Director, Global HEOR • Director, Public Policy and HEOR • Group Manager, Health Economics 17Senior employees from top 50 Pharma
  • 3. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 3 act with confidence What you will learn in this report: • HEOR department operations and structuring, including: Organizational and operational best practices HQ and regional structuring models Departmental headcounts Organizational alignment with Medical Affairs, R&D, and Market Access Division of work (i.e. Headquarters vs. in-country affiliates, the use of “Centers of Excellence”) Involvement in pricing and reimbursement Outsourcing and vendor selection Annual product budgets Challenges Future predictions for promise, growth, models, use of service providers, etc. Recommendations for staff, timing, payer interactions, etc. • Qualities of successful HEOR employees, as well as professional development and group structuring strategies to improve HEOR functional effectiveness • Ways to optimize HEOR work during clinical development delays by identifying barriers and understanding ideal timing of HEOR project kickoff, design, and execution How you can use this report: • Learn from on-the-ground professionals to develop successful and timely HEOR programs that seamlessly integrate with Research & Development to establish a persuasive product narrative • Benchmark the structuring of HEOR resources against Top 50 Pharma to optimize group effectiveness and improve resource development • Identify best practices, recommendations, and challenges for all aspects of HEOR as described by 1 Vice President, 15 Directors, and 1 Group Manager within Top 50 Pharma Up next: Full table of contents and sample pages
  • 4. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 4 act with confidence Table of Contents Full table of contents and additional sample pages available in the full preview, free on our website: http://www.isrreports.com/product/benchmarking-pharma-industrys-heor- functions/
  • 5. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 5 act with confidence act with confidence Introduction www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile 7 Introduction One way to think about the Russian clinical trial and pharmaceutical environment is to think of the country as a publically traded pharmaceutical company� If you were leafing through a prospectus or an investor presentation, you would find a com- pany with strong macro fundamentals, historic growth, inconsistent performance, and some regulatory uncertainty� In short, Russia has many of the same character- istics as a mid-stage pharmaceutical company� And, if you take a portfolio theory approach to investing, you would likely want to invest some portion of your assets in Russia� Why? ↑ Macroeconomics: Russia is the world’s 10th largest economy ↑ International recognition: Joined the World Trade Organization (WTO) in 2012 ↑ Positive balance sheet: Russia has ~$240B trade surplus from fossil fuel reserves ↑ Focus: Putin announced $3�9B plan aimed at having 90% of medicines to be locally produced by 2020 ↑ Reimbursement structure: Medicines Insurance System (Aug 2012) is to be in place by 2020 that will include a tiered rate of reimbursement, depending on the nature of the illness, and improve access to medications ↑ Growth: Russian pharmaceutical market has been growing 17% annually since 2005 ↑ Untapped potential: Many patients are treatment naïve, offering opportunities for clinical trial patient recruitment ↓ Uncertainty: Regulatory environment and customs practices are unstable and unpredictable ↓ Difficult: In 2012 the World Bank ranked Russia 122nd on their list of economies by ease of doing business, 21 spots below China ↓ Skills: Finding highly qualified healthcare professionals can be difficult ↓ Protection: IP protection is concerning Sample Page: Report Introduction Reimbursement is becoming more difficult to obtain and favorable reimbursement is more difficult still. As the pharmaceutical industry adapts to the changing reimbursement environment, Health Economics and Outcomes Research (HEOR) continues to grow in prominence within pharma and is becoming an increasingly important piece of the puzzle in terms of successfully commercializing products. Pharma can no longer simply demonstrate to payers that a product works and is safe and expect reimbursement to be easily checked off the to-do list. Pharma needs to sell the story of a strong value proposition for its products and HEOR is the way to do it. As HEOR is still evolving, ISR wanted to gather a better understanding of HEOR as a function: what types of work HEOR departments do, how HEOR departments are structured, and how they fit within the larger organization. While we’ve found that there are some sub-topics in HEOR in which Top 50 pharma companies subscribe to similar schools of thought, there are also many areas in which large pharma approaches HEOR-related decisions quite differently. ISR presents with this report an opportunity for pharma companies to benchmark their HEOR approach against that of Top 50 pharma companies. ISR will detail what we’ve found to be common approaches as well as explain differing styles so companies can use these assessments as a yard stick against which to measure their own HEOR structure.
  • 6. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 6 act with confidence Sample Page act with confidence Understanding the HEOR Function www.ISRreports.com ©2013 | Benchmarking the Pharma Industry’s HEOR Functions 12 Employee Qualities Qualities of Successful HEOR Employees Technical expertise Strong communication skills Strong business sense or skillset Ability to strategize and see the ‘big picture’ Understanding of marketing Understanding of the product and therapy area Qualities of successful HEOR employees were also discussed� HEOR employees are expected to have strong communication skills as they interface with many groups within the organization as well as with outside vendors� Business skills and the ability to see the ‘big picture’ are also noted as critical factors in effective HEOR work� “It’s hard to take someone right out of school and put them in an outcomes research job� They really need to have a business sense� There are people that are extremely technically proficient but don’t necessarily have the business skills to provide the strategic insight which is equally if not more important than the technical expertise� It’s really understanding the strategic piece of it that is more of a challenge� That’s where business and experience lend themselves” (Top 10 Pharma)� Marketing experience is also noted as key� Being able to understand the product lifecycle helps employees decide what type of evidence is needed and then helps to disseminate that information effectively within the marketplace� “It’s about how you take the modeling from theory to practice� A lot of modeling is theoretical but you need someone to be able to deliver the model in front of the customer in a more practical sense” (Top 25 Pharma)� Employees are also expected to know a good deal about the actual product and/or indication on which they are working� “You really need to learn the indication and its idiosyncrasies�” One respondent mentioned that she expects to see HEOR employees being moved around the organization to achieve more cross- functional experience and learn more about the products� A handful of respondents mention that competition for quality HEOR employees is very high and the pool of talented employees is rather shallow� There is a lot of job switching within the field and salaries and titles continue to rise for HEOR employees� One respondent receives at least two phone calls or emails per week from recruiters for HEOR positions at competing companies� Pharmaceutical organizations are reportedly always on the lookout for well-qualified, experienced employees� It’s about how you take the modeling from theory to practice. A lot of modeling is theoretical but you need someone to be able to deliver the model in front of the customer in a more practical sense.” (TOP 25 PHaRMa)
  • 7. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 7 act with confidence Sample Page Full table of contents and additional sample pages available in the full preview, free on our website: http://www.isrreports.com/product/benchmarking-pharma-industrys-heor- functions/
  • 8. act with confidence Ordering Information Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services indus- tries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www. ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. About Industry Standard Research Save on this, or any ISR report, by registering a free account Register now • Receive a $250 instant credit towards any ISR report • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources For pricing and ordering information, please visit our website: http://www.isrreports.com/product/benchmarking-pharma-industrys-heor- functions/
  • 9. www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 9 act with confidence The ISR Difference Custom-quality syndicated market research www.ISRreports.com ISR's Reports The Common Syndicated Reportvs. How confident are you? vs. DataCollection ISR's proprietary data collection tools and channels support fast, high quality data collection Struggle to recruit the right targets and enough of them vs. SampleSizes Robust sample sizes that instill confidence Often insufficient industry representation that leaves you defending results vs.vs. Research methods Mostly primary research; always appropriate for the topic One size fits all; usually publically available data vs.vs. Respondents Sophisticated screening ensures genuine decision-makers Undisclosed methodologies and respondent demographics vs.vs. Analysts Decades of experience means more insights that are immediately usable Junior analysts capable of reporting numbers